Characterization of the medical department of pharmaceutical companies operating in Portugal

• Autor(a) principal: Gala, Acílio
• Data de Publicação: 2017
• Outros Autores: Lima, Ana Rita, Laranjeira, Luís, Ramos, Miguel, Guimarães, João Paulo, Sousa, Conceição, Leitão, Andreia, de Jesus, Paula Martins, Marques, Susana Castro, Pereira, Carla, Nogueira, Mafalda, Sequeira, Leonor, Lopes, Nelson, Ribeiro, Filipe, Pinto, Paula C. A. G., Gago, Bruno
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://doi.org/10.25756/rpf.v9i2.139

In a context of strong regulatory demands and high economic pressures and constraints, medical departments within pharmaceutical companies, have demonstrated its strategic relevance even though the functions to embrace are not globally consensual.In this context, a study that intended to analyse the management of medical activities, in pharmaceutical companies operating in Portugal, including allocated human resources and investment trends, was implemented.Quantitative information was collected through an electronic survey, in pharmaceutical companies with activity in Portugal.The analysis of the results supported the conclusion that the majority of the companies are affiliates of international companies and that 79% of them have formalized medical departments. The human resources of the medical departments of the participant companies include several professional classes, with predominance of pharmacists. Globally, the number of employees of the medical area has registered a systematic growth in the last years. It was also possible to conclude that the majority of the companies are increasing the investment in medical affairs activities.This study enables the understanding of these activities in pharmaceutical companies operating in Portugal, within the international panorama of pharmaceutical industry. It contributes to improve the knowledge about the relevance of medical departments while enabling the definition of novel pathways to increase the competiveness and sustainability of the companies.